News and Events
|
Research Feature
Sickle cell disease (SCD) is a group of painful and life-threatening genetic disorders that affect hemoglobin, the major protein that carries oxygen in red blood cells. It occurs in nearly 100,000 people in the United States and millions worldwide. The most common type is hemoglobin SS (HbSS), which affects about 65% of those with sickle cell...
|
Research Feature
The aorta, one of the “great arteries,” carries blood away from the heart to support circulation throughout the body. However, sometimes a tear in the lining of the aorta can occur, and while this is uncommon, it often requires immediate treatment. That’s why it’s important for people to be aware of common risk factors and symptoms. Sujata M...
NIH-supported clinical trial is the first positive trial for treatment of hereditary hemorrhagic telangiectasia A clinical trial supported by the National Institutes of Health (NIH) was stopped early after researchers found sufficient evidence that a drug used to treat bone marrow cancer and Kaposi sarcoma is safe and effective in treating...
|
News Release
A scientific team supported by the National Institutes of Health (NIH) has created a preclinical blood test to identify adults most likely to develop severe respiratory conditions, including chronic obstructive pulmonary disease ( COPD). The blood test analyzes 32 proteins that scientists determined accurately predicted an adult with an increased...
Upcoming Events
Join the Learn More Breathe Better® program and guest speakers from the Breathe Better Network as we discuss how people in all stages of life can protect their lungs from COPD and how people living with the disease can manage it. We will also highlight educational resources available to use during National COPD Awareness Month in November and beyond.
Virtual
2:00 p.m. - 3:00 p.m. ET
2:00 p.m. - 3:00 p.m. ET
The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) is hosting a two-day virtual workshop titles "Disparities across the spectrum of pulmonary vascular disease (PVD)" - scheduled for October 22 - 23, 2024, from 10:00 AM to 5:40 PM (EST).
October
22
-
23
,
2024
Virtual (webinar)
October 22, 2024, 10:00 a.m. - 5:30 p.m. EST
October 23, 2024, 10:00 a.m. - 5:40 p.m. EST
October 22, 2024, 10:00 a.m. - 5:30 p.m. EST
October 23, 2024, 10:00 a.m. - 5:40 p.m. EST
The NHLBI has been focusing on heart, lung, blood, and sleep (HLBS) disorders and exploring technologically-based solutions to improve health. After a virtual workshop in May 2022, they identified opportunities for pursuing synthetic biological tools in the context of these disorders and signed onto the Notice of Special Interest for Synthetic Biology for Biomedical Applications. The NHLBI aims to establish partnerships between scientists and bioengineers to develop synthetic biological tools targeting HLBS disorders, with the goal of addressing obstacles and encouraging applications leading to a peer-reviewed whitepaper detailing progress and outcomes.
November
4
-
5
,
2024
Virtual
12:00 p.m. - 5:00 p.m. ET
12:00 p.m. - 5:00 p.m. ET
Featured Past Events
The meeting of the National Commission on Lymphatic Diseases scheduled for September 30, 2024 bring together a multidisciplinary panel of stakeholders and experts who are at the forefront of their respective fields. The planned discussions will play a crucial role in shaping the conversation to improve fundamental knowledge, implementation of practice guidelines, and addressing gaps and disparities in the diagnosis, therapeutics, and access to care for lymphatic disease (LD).
Virtual
9:10 a.m. - 2:20 p.m. ET.
9:10 a.m. - 2:20 p.m. ET.
Obesity contributes to diseases of the heart-including atherosclerotic cardiovascular disease, arrhythmias, and heart failure with preserved ejection fraction-which often are refractory to treatment. This symposium explores the epidemiology and pathophysiology of obesity-related heart diseases, as well as the role of emerging therapeutics and issues related to prevention, access to treatment, and health equity.
Virtual (webinar)
9:00 am - 3:00 pm (ET)
9:00 am - 3:00 pm (ET)
The NHLBI is hosting the Annual NHLBI Sickle Cell Disease Research Meeting from August 12-14, 2024. This three-day hybrid meeting aims to facilitate discussions around ongoing research and new developments in sickle cell disease, while also offering a platform for participants to network with fellow investigators and NHLBI program staff.
August
12
-
14
,
2024
William H. Natcher Conference Center, building #45
45 Center Drive Bethesda, MD 20892
August 12, 2024 - 9:00 a.m. - 5:00 p.m. ET
August 13, 2024 - 9:00 a.m. - 4:30 p.m. ET
August 14, 2024 - 9:00 a.m. - 4:00 p.m. ET
45 Center Drive Bethesda, MD 20892
August 12, 2024 - 9:00 a.m. - 5:00 p.m. ET
August 13, 2024 - 9:00 a.m. - 4:30 p.m. ET
August 14, 2024 - 9:00 a.m. - 4:00 p.m. ET
